WEHI-345 analog is a selective inhibitor of the RIPK2 kinase, primarily utilized in biomedical research for studying cell signaling pathways, apoptosis, and immune responses. It serves as a valuable tool for investigating the role of RIPK2 in cellular processes related to inflammation and autoimmune diseases, such as Crohn's disease and rheumatoid arthritis, as well as its potential involvement in cancer. Researchers use this compound to explore therapeutic targets by modulating kinase activity, aiding in the development of novel anti-inflammatory drugs and targeted therapies. Additionally, it is employed in preclinical studies to assess efficacy and safety in inhibiting specific pathways, contributing to advancements in personalized medicine.